AdAlta Limited

AdAlta Limited is an Australia-based clinical-stage drug discovery company. The Company is engaged in the development of therapeutic products from its i-body platform. The Company has five active development programs ranging from discovery to Phase II clinical trials with applications in the fields of inflammation/fibrosis and immuno-oncology. Its lead product, AD-214, is an antibody therapeutic for the treatment of fibrotic diseases, including lung fibrosis (specifically Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD)), kidney fibrosis, eye fibrosis and some cancers. Chimeric Antigen Receptor (CAR) cell therapies involve modification of a patient’s immune cells (T cells, NK cells, macrophages and other) so that they produce a CAR on the cell surface that enables the patient’s immune system to recognize and kill diseased cells such as cancer. It develops i-body enabled PET (i-PET) imaging agents for use in immuno-oncology. It evaluates several CXCR4 i-bodies.